Abstract:Introduction Dual Specific Protein Phosphatases (DUSPs) are a family of proteins that dephosphorylate both tyrosine and serine/threonine residues in biological systems and play multiple and diverse role in cells. The clinical impact of the protein phosphatase family has not been well explored in solid tumours. The present study investigated the role of DUSP-7 (also known as PYST2), a protein phosphatase that dephosphorylates mitogen activated protein kinase (MAPK), c-Jun N-terminal kinase (JNK) and p38 which are important regulators of solid tumours and cancer cells, in pancreatic cancer. Methods Pancreatic cancer tissues from patients who underwent resections were obtained immediately after surgery, stored and subsequently processed for quantitative analyses of DUSP-7 gene transcript. The expression levels were correlated with the survival and pathological parameters of the patients. Human pancreatic cancer cell line, PANC1 was used in creation of a DUSP-7 knockdown (by way of siRNA) cell model and was assessed for the impact of DUSP-7 on the biological functions by various cell based assays. Results Pancreatic tumour tissues displayed significantly lower levels of DUSP-7 transcript than normal tissues (p=0.0031). Kaplan-Meier Survival analysis showed that patients with high levels of DUSP-7 had a significantly longer survival than those with low levels (p=0.021 (Mansel-Cox log rank test), mean survival 30.2 months for high levels vs 17.0 months for low levels). This survival benefit was particularly seen in tumours with low levels of Her-2 expression. It is noted that while high grade tumour had low levels of DUSP-7, the same trend was found with TNM tumours of which high TNM tumours had lower DUSP-7. Tumours with metastatic lymph nodes had marginally higher levels of DUSP-7 than node negative tumours. The presence of microvascular embolism (p=0.015) and levels of DUSP-7 (p=0.044) were two prognostic indicators of the patients. Knocking down DUSP-7 from PANC1 cancer cells rendered the cell to be less mobile and less adhesive as assessed by way of electric cell-substrate impedance sensing (ECIS). Conclusions Dual Specific Protein Phosphatase, DUSP7/PYST2 is aberrantly expressed in pancreatic cancer and is a positive survival indicator of the patients.

Deubiquitinase PSMD7 facilitates pancreatic cancer progression through activating Nocth1 pathway via modifying SOX2 degradation

PSMD7 downregulation suppresses lung cancer progression by regulating the p53 pathway

Ubiquitin-specific peptidase 22 in cancer

Deubiquitinating enzyme PSMD7 promotes bladder cancer development: Involvement of RAB1A stabilization

Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma

Depletion of the Proteasome Subunit Psma7 Inhibits Colorectal Cancer Cell Tumorigenicity and Migration

O-GlcNAcylation and stablization of SIRT7 promote pancreatic cancer progression by blocking the SIRT7-REGγ interaction

USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation.

Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A

PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of β-catenin and PD-L1

Ubiquitin-Specific Peptidase 7: A Novel Deubiquitinase That Regulates Protein Homeostasis and Cancers

OTU-17 Expression, Clinical and Prognostic Value of Dual Specific Protein Phosphatase-7 (DUSP-7) in Pancreatic Cancer

USP28 promotes tumor progression and glycolysis by stabilizing PKM2/Hif1-α in cholangiocarcinoma

Deubiquitinase PSMD14 promotes tumorigenicity of glioblastoma by deubiquitinating and stabilizing β‐catenin

PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling

PSMD2 contributes to the progression of esophageal squamous cell carcinoma by repressing autophagy

Ubiquitin signaling in pancreatic ductal adenocarcinoma

PSMD11 promotes the proliferation of hepatocellular carcinoma by regulating the ubiquitination degradation of CDK4

OTUD7B Deubiquitinates LSD1 to Govern Its Binding Partner Specificity, Homeostasis, and Breast Cancer Metastasis

DDX3X interacts with SIRT7 to promote PD-L1 expression to facilitate PDAC progression

PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERα